Navigation Links
Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel
Date:3/23/2011

EAST NORRITON, Pa., March 23, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, today announced the addition of two renal research and clinical experts, Ben Humphreys, M.D., Ph.D. and Giuseppe Remuzzi, M.D., F.R.C.P., from the Harvard Stem Cell Institute and Mario Negri Institute respectively, to its panel of Research & Development Advisors. This panel provides counsel to Tengion and engages leading researchers, clinicians, and patient advocates with the company as it advances its Organ Regeneration Platform™. The newest additions to the panel will work with Tengion in the area of renal function and chronic kidney disease (CKD) as the Company continues to advance its Neo-Kidney Augment™ program. The Neo-Kidney Augment, which is designed to delay or prevent the need for dialysis or kidney transplantation in patients at risk of chronic kidney failure, has demonstrated consistently positive data that Tengion scientists have published or presented in four different animal models of kidney failure, including in large animals.  

"The appointment of these leaders to our advisory panel will provide Tengion with rich insights as we work to advance our Neo-Kidney Augment to clinical trials," said Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion. "There is a great need for new treatments for patients with chronic kidney disease," stated Dr. Remuzzi. "I look forward to helping Tengion identify the most rapid and efficient pathways to clinical trials." Dr. Humphreys added, "The recent preclinical findings for Tengion's Neo-Kidney Augment show that innovative approaches are beginning to offer promising results. I am enthusiastic about working with Tengion to explore these findings and further advance development."

Joining Tengion's panel of Research & Development Advisors are:

Giu
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
2. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
3. Tengion Announces Second Closing of Series C Financing
4. Tengion to Present at the Piper Jaffray 20th Annual Healthcare Conference
5. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
6. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
7. Tengion Appoints A. Brian Davis Chief Financial Officer
8. Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
9. Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
10. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
11. Tengion to Present at the 13th Annual BIO CEO & Investor Conference and the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Nashville Fertility Center announced that ... the American Society for Reproductive Medicine (ASRM), a leading ... reproductive medicine. In his new role as treasurer, ... board and will have a voice in furthering the ... supported ASRM since 1984 when he joined while conducting ...
(Date:12/24/2014)... PharmaBoardroom,s new report, , Healthcare and ... free download , digs deep into this vibrant market, ... sector today. One area where Algeria ... a homegrown pharmaceutical manufacturing base, even if the government,s ambitious ... off. A cursory comparison with neighboring Morocco ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... BRANFORD, Conn., May 21, 2012  HistoRx, the leader ... proprietary AQUA technology to assessment of messenger RNA ... standardization of protein in tissue specimens; this new ... analysis to quantification of nucleic acids.  ...
... PANAMA CITY, Panama, May 21, 2012 International ... 2012 to discuss the potential use of Oxitec,s genetically modified ... Dengue Fever in Panama. The independent forum was ... Memorial Institute for Health Studies and the University of Panama. ...
... 2012  Neuralstem, Inc. (NYSE MKT: CUR) announced that ... the World Stem Cells & Regenerative Medicine Congress ... 22nd at 12:30 PM. Mr. Garr,s presentation, "Stem ... cellular therapy trial in ALS, its neurogenic small ...
Cached Biology Technology:AQUA® Technology Uses Extend Beyond Protein: Effective measurement of messenger RNA now demonstrated 2AQUA® Technology Uses Extend Beyond Protein: Effective measurement of messenger RNA now demonstrated 3Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 2Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 3Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London 2
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/10/2014)... December 9, 2014   ... Platform   Jifflenow, ... scheduling solutions for business-to-business (B2B) events, today announced ... in mobile near-field communication (NFC), Bluetooth low energy ... (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... have added one more trick to the amazing repertoire ... signals to nerve cells. , Nanotubes, tiny hollow carbon ... hair, are already famed as one of the most ... as steel and one-sixth as dense, able to conduct ...
... 2006 is shaping up as the worst year for California's ... of evolution and ecology at UC Davis. , That's a ... migrated through the Central Valley. But other species have seen ... region altogether. , "It has been the worst spring for ...
... used in Chinese medicine to treat the symptoms of ... reverses some of the pancreatic dysfunctions that underlie the ... Metabolism. The chemical therefore represents a useful starting point ... drug could offer a big advance, the group added, ...
Cached Biology News:Nanotubes used for first time to send signals to nerve cells 2Where have all the butterflies gone? 2Gardenia fruit compound starting point for diabetes therapy 2
Polymerase (RNA) II (DNA directed) polypeptide L...
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... of ICE-family proteases/caspases initiates apoptosis in mammalian ... Detection Kit provides a simple and convenient ... flow cytometry in intact cells. The ... aspartate residues linked to rhodamine 110 (D2R), ...
Biology Products: